Sensient Technologies Corp (SXT) Q4 2024 Earnings Call Highlights: Robust Growth in Revenue and ...
Fourth Quarter Revenue: $376.4 million, up from $349.3 million in the previous year.
Fourth Quarter Operating Income: $42 million, compared to $8.1 million in the prior year.
Adjusted Operating Income: $42.9 million in Q4 2024, a 20.8% increase in local currency.
Local Currency Revenue Growth: 8.9% in Q4 2024.
Local Currency Adjusted EBITDA Growth: 18.8% in Q4 2024.
Local Currency Adjusted EPS Growth: 29.4% in Q4 2024.
Full Year Revenue Growth: 7.4% in local currency for 2024.
Full Year Adjusted EBITDA Growth: 8.3% in local currency for 2024.
Color Group Revenue Growth: 14% in Q4 2024, 7.3% for the full year.
Color Group Operating Profit Growth: 27.4% in Q4 2024, 14.2% for the full year.
Color Group Adjusted EBITDA Margin: 22.1% for the full year, up 110 basis points.
Flavors and Extracts Revenue Growth: 3.4% in Q4 2024, 7.1% for the full year.
Flavors and Extracts Operating Profit Growth: 18.4% in Q4 2024, 10.8% for the full year.
Flavors and Extracts Adjusted EBITDA Margin: 16.1% for the full year, up 30 basis points.
Asia Pacific Group Revenue Growth: 25.2% in Q4 2024, 13% for the full year.
Asia Pacific Group Operating Profit Growth: 41.7% in Q4 2024, 14.1% for the full year.
Asia Pacific Group Adjusted EBITDA Margin: 22.7% for the full year.
Free Cash Flow: $98 million in 2024, up 19.7% from 2023.
Total Debt: $633 million as of December 31, 2024.
Net Debt to Credit Adjusted EBITDA: 2.3 times as of December 31, 2024.
Capital Expenditures: $59 million in 2024, expected to be $70 million to $80 million in 2025.
2025 Revenue Guidance: Mid-single digit local currency growth expected.
2025 Adjusted EBITDA Guidance: Mid to high-single digit local currency growth expected.
2025 Adjusted EPS Guidance: High single digit to double digit local currency growth expected.
Warning! GuruFocus has detected 4 Warning Signs with EHMEF.
Release Date: February 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Sensient Technologies Corp (NYSE:SXT) reported strong fourth quarter results with 8.9% local currency revenue growth and 18.8% local currency adjusted EBITDA growth.
The Color group achieved 14% local currency revenue growth and 27.4% local currency operating profit growth in Q4 2024.
The Asia Pacific Group delivered exceptional performance with 25.2% local currency revenue growth and 41.7% local currency operating profit growth in Q4 2024.
The company successfully reduced its leverage ratio to 2.3 at the end of 2024 from 2.6 at the end of 2023.
Sensient Technologies Corp (NYSE:SXT) anticipates continued growth opportunities in natural colors, driven by increasing consumer demand and regulatory shifts.
Foreign currency translation reduced EPS by approximately 1% in the fourth quarter of 2024.
The company faces potential headwinds from tariffs, which could impact pricing and profitability.
Sensient Technologies Corp (NYSE:SXT) expects a foreign exchange headwind of approximately $0.10 to $0.15 in 2025.
The conversion from synthetic to natural colors may lead to some gross margin erosion due to higher raw material costs.
The first quarter of 2025 is expected to start slowly, with projected local currency revenue growth between 3% and 5%.
Q: Can you provide more specifics on the increase in activity and business wins related to natural products, particularly in flavors and extracts? A: Paul Manning, CEO, explained that the company saw double-digit growth in revenue and volume for natural colors in their food colors business. Approximately 80% of new product launches globally contain natural colors, and some existing brands are converting from synthetic to natural colors, which has positively impacted the top and bottom lines. The conversion to natural colors is seen as a significant opportunity for Sensient.
Q: What is the margin differential between natural and synthetic colors, and how does the 10x volume differential impact costs for customers? A: Paul Manning, CEO, noted that the raw material cost of synthetic colors is very low in packaged products. While natural colors may increase costs, they still represent a small portion of overall raw material expenses. Sensient expects revenue to increase with natural colors, with potential erosion in gross margin but stable operating profit margins due to a relatively fixed SG&A base.
Q: Can you provide an estimate of the penetration rate of natural colors in the US market compared to Europe? A: Paul Manning, CEO, stated that in Europe, over 80% of the market has converted to natural colors, while in the US, about one-third of the market has converted. Latin America has a penetration rate of 25% to 30%, and Asia Pacific varies by country, with Japan having a high conversion rate and China being lower.
Q: What is driving the strong growth in the Asia Pacific region, and what underpins the high single-digit growth outlook for 2025? A: Paul Manning, CEO, attributed the growth to years of investment in the region, focusing on elevating the portfolio, sales force, and technical applications. The region has seen significant new sales wins and geographic expansion. The high single-digit growth outlook is supported by continued strategy execution and emphasis on new wins and customer service.
Q: Are there any other synthetic color compounds besides red 3 being considered for regulation or conversion to natural colors? A: Paul Manning, CEO, mentioned that while red 3 is small, other synthetic colors like red 40, yellow 5, and yellow 6 are being considered in state legislation. The FDA has only banned red 3 so far, but market dynamics and potential state actions could drive further conversions to natural colors.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential
Brookfield Infrastructure has increased its high-yielding payout every year since its formation. PepsiCo is an elite dividend stock. Prologis is growing its dividend much faster than the average dividend stock. 10 stocks we like better than PepsiCo › Dividend-paying stocks can be great investments. They can enable you to generate some passive income, providing a real return. In addition, dividend stocks have historically produced strong total returns as they've grown their earnings and shareholder payouts, driving stock price appreciation. Brookfield Infrastructure (NYSE: BIPC)(NYSE: BIP), PepsiCo (NASDAQ: PEP), and Prologis (NYSE: PLD) currently stand out among dividend stocks. The trio has excellent records of paying growing dividends. On top of that, they currently offer attractive yields of more than 3%, partly due to drops in their stock prices this year. Because of that, they offer compelling blends of dividend income and upside potential. Shares of Brookfield Infrastructure have declined by nearly 10% from their 52-week high. That slump has pushed the global infrastructure company's dividend yield up to 4.2%. The company's stock price has also slumped, even though it's having another good year, and its funds from operations (FFO) rose 5% in the first quarter, powered by inflation-driven rate increases, recently completed expansion projects, and acquisitions closed in the past year. Brookfield Infrastructure has a terrific record of paying dividends. It has increased its payment in all 16 years since its formation, growing it at a 9% compound annual rate. The company expects to continue increasing its payout in the future, targeting 5% to 9% annual growth. It sees a trio of organic growth drivers (inflation-driven rate increases, volume growth as the global economy expands, and expansion projects), increasing its FFO per share by 6% to 9% per year. On top of that, the company has an excellent record of making accretive acquisitions funded by recycling capital. It recently agreed to invest $500 million in the acquisition of Colonial Enterprises, which owns a leading U.S. refined products pipeline system. It also partnered with GATX Corporation to buy Wells Fargo's rail operating lease portfolio (consisting of 105,000 railcars) for $4.4 billion. It's also acquiring Wells Fargo's rail finance lease portfolio (23,000 railcars and 440 locomotives) in a separate deal. Brookfield estimates that acquisitions like these will help push its FFO growth rate above 10% annually. PepsiCo stock has slumped more than 25% from its 52-week high. That plunge has propelled its dividend yield to 4.4%. That's a tasty level for a company with a long history of satisfying investors' cravings for more dividend income. The food and beverage giant recently increased its dividend payment by another 5%. That extended its growth streak to 53 straight years, enough to qualify PepsiCo as an elite Dividend King. PepsiCo's stock is down due to concerns that tariffs, a slowing economy, and changing consumer tastes will impact the company's growth. On the one hand, the company is seeing some impact from those headwinds this year. It now expects its earnings per share to be at the same level as last year's, compared to the mid-single-digit growth rate it initially expected. However, the company has a resilient business and expects its growth to reaccelerate in the coming years. It has been investing heavily in the strategic transformation of its portfolio to healthier food and beverage options, including buying Poppi, Siete, and Sabra in recent quarters. These investments should pay dividends for the company in the coming years by reigniting its earnings growth engine, which should enable PepsiCo to continue increasing its dividend. Prologis stock has slumped more than 15% this year. That sell-off has helped nudge its dividend yield up to 3.7%. The leading industrial real estate investment trust (REIT) has been under some pressure due to slowing demand for warehouse space. However, the company is still performing well amid all the uncertainty. Its core FFO per share increased 11% in the first quarter as it continues to sign new leases at much higher rates compared to the price point of expiring contracts on the same space. Meanwhile, the long-term demand picture for warehouse space remains robust. "Over the long term, limited new supply and high construction costs support continued rent growth," commented CEO and co-founder Hamid Moghadam in the first-quarter earnings press release. That should enable the company to capture higher rental rates on its existing properties and continue developing new warehouses. In addition, Prologis is using some of its land to build data centers to capitalize on the growing demand for these properties to support increased digitalization and AI technology. Prologis' growth prospects should enable the REIT to continue increasing its dividend. It has grown its payout at a 13% compound annual rate over the past five years. That's faster than the S&P 500 (5%) and REIT sector average (6%). Brookfield Infrastructure, PepsiCo, and Prologis offer investors the best of both worlds. They pay dividends that yield more than double the S&P 500's average (less than 1.5%), and they have compelling upside potential from their earnings growth and an eventual recovery in their stock prices. Because of that, they could produce strong total returns from here, making them great dividend stocks to buy right now. Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Matt DiLallo has positions in Brookfield Infrastructure, Brookfield Infrastructure Partners, PepsiCo, and Prologis. The Motley Fool has positions in and recommends Prologis. The Motley Fool recommends Brookfield Infrastructure Partners and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. 3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential was originally published by The Motley Fool
Associated Press
5 hours ago
- Associated Press
Lead Plaintiff Deadline is June 16, 2025 for Investors of Ibotta, Inc.
NEW YORK, NY - June 8, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) on behalf of Ibotta investors. CLICK HERE TO JOIN THE CASE If you are an investor in Ibotta and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than June 16, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to consumers through the Ibotta Performance Network. On April 18, 2024, Ibotta conducted its Initial Public Offering ('IPO'), offering 6,560,700 million shares of Class A common stock at a price of $88 per share. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that; (i) Ibotta's data measurement system did not provide accurate, precise, and real time client campaign and consumer data measurement; (ii) the Company's business mix had shifted and was generating less revenue; and (iii) Ibotta had 'exhausted' its clients' budgets, negatively impacting fourth quarter 2024 revenue and expected first quarter 2025 revenue. According to the action, on February 26, 2025, after market hours, in connection with reporting fourth quarter 2024 and full year 2024 financial results, Ibotta's CEO Bryan W. Leach ('CEO Leach') explained just how deficient Ibotta's data measurement technology was by stating that 'it has become clear that we need to bring to market a more rigorous form of measurement that goes beyond the industry standard return on ad spend, or ROAS, framework.' Further CEO Leach allegedly announced that Ibotta would transform into a programmatic advertising company, which according to the complaint demonstrates that, at the time of the IPO, Ibotta's data measurement infrastructure was not suited for heavy reliance on third party platforms. On this news, the price of Ibotta's stock fell $29.08, or nearly 46%, to close at $34.09 on February 27, 2025, more than 60% lower than the IPO price of $88 per share. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on
Yahoo
7 hours ago
- Yahoo
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
Hims & Hers is gaining market share in the telehealth sector and has a long runway to disrupt the healthcare industry. It is acquiring a company in order to enter Europe. The stock is expensive, but it may still be a great investment over the long term. 10 stocks we like better than Hims & Hers Health › Telehealth has gone through a major boom-and-bust cycle. One promising stock emerging from the bust is Hims & Hers (NYSE: HIMS). Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, the company is taking a lot of share in the telehealth market. The stock has traded up 449% since going public, and it is up a staggering 158% in the past year. Disruptive innovation helped bring shareholders of Hims & Hers stock major gains. But does that make the stock a buy today? People in the United States get frustrated dealing with health insurance -- as you may know from personal experience. Hims & Hers aims to slowly disrupt the market with an innovative approach that bypasses insurers. It helps customers easily get generic medications that help deal with sexual health, hair loss, mental health, and other common concerns, by having prescriptions and shipments sent straight to their doors through monthly subscriptions. This model has helped Hims & Hers dominate the telehealth prescription market and reach $1.78 billion in trailing-12-month revenue. It's now trying to further expand its offerings by adding the branded weight loss drug Wegovy to its marketplace through a partnership with Novo Nordisk (NYSE: NVO). Previously, Hims & Hers sold weight loss drugs under an exemption because of supply shortages for the products, but with those shortages now resolved, it has to work with patent holders such as Novo Nordisk. Along with weight loss, it's also aiming to get into testosterone and menopause-related prescriptions. Today, Hims & Hers has 2.4 million active customers. Management believes there are over 100 million people who could utilize one of its products, giving the company a huge runway to grow. A key factor will be the new partnership for marketing Wegovy, which is an expensive subscription at an introductory discount offer of $549 a month. Usage of such drugs is growing like a weed, and could be a new growth avenue for Hims & Hers to pursue. Another huge step for Hims & Hers is international expansion. While countries vary in their approaches to healthcare and insurance, most people want easy-to-use products, affordable prices, and convenient at-home shipping regardless of where they live. Management hopes to supercharge international growth with its proposed buyout of competitor Zava in Europe. Zava serves the western European market with 1.3 million active customers in the United Kingdom, France, Germany, and Ireland. The combined company can utilize Hims & Hers' marketing expertise, increasing scale, and partnerships to bring this sought-after model to Europe. Global disruption of the healthcare space will give Hims & Hers an even larger runway for growth, while also allowing it to invest in new innovations -- including at-home patient testing and its own compounding manufacturing facility. Hims & Hers has grand ambitions to disrupt healthcare with its direct-to-consumer model, and Zava will give it even more scale to keep accelerating growth. It will be exciting to see what the combined company can do over the next decade. You can feel the excitement with Hims & Hers and its explosive revenue growth. Sales grew 111% year over year last quarter, and are expected to hit at least $2.3 billion in 2025. (They were just $100 million in 2020.) The company has a goal of reaching $6.5 billion in sales by 2030, which would make it one of the fastest-growing companies in the world this decade. This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, which is a high trailing earnings multiple even for a fast-growing company. However, revenue is growing so quickly and with such high margins that the company may grow into this high valuation by the end of the decade. As noted, management has a goal of $6.5 billion in revenue in 2030. With 20% bottom-line profit margins -- easily doable with 77% gross profit margin over the last 12 months -- that would equate to roughly $1.3 billion in annual earnings in 2030. Today, the market cap is $12.3 billion, which would mean a P/E of just around 9.5 by 2030 if the market cap did not change (which is an unlikely scenario, but demonstrates that there is potential for the valuation to drop). Even with some shareholder dilution that raises the number of shares outstanding, the stock would be trading at a P/E of around 10 to 12 at the current share price (which is also likely to change). If you believe this rapid growth will continue over the long term, Hims & Hers stock will grow into its valuation. If you have any doubts about this pace of growth, shares should be considered overvalued at the moment. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space was originally published by The Motley Fool
